View Financial HealthBioethics 배당 및 자사주 매입배당 기준 점검 0/6Bioethics 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 01Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2025, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Aug 15Bioethics, Ltd. announced delayed 10-Q filingOn 08/14/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Jun 27SILQ Technologies Corporation entered into a non-binding letter of intent to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction.SILQ Technologies Corporation entered into a non-binding letter of intent to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction on June 18, 2024. All outstanding shares of SILQ would then be converted into shares of Bioethics common stock pursuant to the definitive merger agreement. Following the closing of the transaction, the parties’ current intention and expectation as set out in the Letter of Intent is that the stockholders of SILQ would own approximately 89% of the fully diluted total outstanding stock of Bioethics, and the stockholders of Bioethics immediately prior to the closing of the transaction, including all current stockholders and all shares to be issued prior to the closing as more fully described in the Letter of Intent, would own 11% of the total outstanding stock of Bioethics following the transaction. In connection with the proposed Merger, Bioethics has agreed to consummate a 1-for-2 reverse stock split. Prior to the proposed Merger, Bioethics intends to issue common or preferred stock convertible into common stock in order to raise money to pay down debt and incentivize and otherwise compensate Bioethics’ officers, directors and consultants, who have not received cash compensation for years. It is currently anticipated that following the closing of the proposed Merger, that there will be at least 50,450,000 shares of Bioethics common stock issued an outstanding. This anticipated post-transaction outstanding stock will include the current outstanding shares of Bioethics after a 1-for-2 reverse stock split, meaning that the ownership of Bioethics of the current Bioethics stockholders, exclusive of all shares to be issued between now and the closing of the transaction, as a percentage of all anticipated outstanding stock will be approximately 1% of all outstanding Bioethics stock following the closing of the transaction. The transaction is subject to due diligence review.공시 • May 17Bioethics, Ltd. announced delayed 10-Q filingOn 05/15/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 02Bioethics, Ltd. announced delayed annual 10-K filingOn 04/01/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2023, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 16Bioethics, Ltd. announced delayed 10-Q filingOn 05/15/2023, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Aug 16Bioethics, Ltd. announced delayed 10-Q filingOn 08/15/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 17Bioethics, Ltd. announced delayed 10-Q filingOn 05/16/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 01Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Aug 17Bioethics, Ltd. announced delayed 10-Q filingOn 08/16/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 18Bioethics, Ltd. announced delayed 10-Q filingOn 05/17/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 02Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Nov 17Bioethics, Ltd. announced delayed 10-Q filingOn 11/16/2020, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Aug 06XCR Diagnostics, Inc. entered into a non-binding term sheet to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction.XCR Diagnostics, Inc. entered into a non-binding term sheet to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction on July 29, 2020. Pursuant to the term sheet, Bioethics will issue 34.2 million shares of Bioethics common stock post one-for-ten reverse stock split. Bioethics and certain of its creditors and affiliates agree to settle down all the liabilities of Bioethics except for $0.2 million. Post completion of the transaction and reverse stock split stockholders of XCR Diagnostics will have the majority share of Bioethics and XCR Diagnostics will become a financially consolidated subsidiary of Bioethics. Mark Scharmann and Elliott Taylor affiliates of Bioethics agrees to lock-up/leak-out agreement governing their shares. Bioethics will raise at least $0.3 million in a private placement within 90 days of closing. At closing, directors of Bioethics and XCR Diagnostics will resign and XCR Diagnostics will have the right to appoint all the directors of Bioethics. The initial directors are expected to be Mark Powelson, Mark Bagnall, Bruce Chafin, Chuck Morrison and Lynda Merrill. Board advisors will be Brian Caplin and Mark Scharmann. The transaction closing is subject to completion of due diligence of XCR Diagnostics by Bioethics, execution of reverse stock split, execution of definitive agreement document, obtaining necessary third party approvals, approval of the board of Bioethics and XCR Diagnostics, approval by the shareholders of Bioethics and XCR Diagnostics and the term sheet requires Bioethics to complete the private placement. The transaction is expected to close by or before August 28, 2020.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 BOTH 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: BOTH 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Bioethics 배당 수익률 vs 시장BOTH의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (BOTH)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Capital Markets)2.1%분석가 예측 (BOTH) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 BOTH 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 BOTH 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 BOTH 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: BOTH 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/02/10 17:17종가2025/11/13 00:00수익2024/12/31연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Bioethics, Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Apr 01Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2025, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Aug 15Bioethics, Ltd. announced delayed 10-Q filingOn 08/14/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Jun 27SILQ Technologies Corporation entered into a non-binding letter of intent to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction.SILQ Technologies Corporation entered into a non-binding letter of intent to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction on June 18, 2024. All outstanding shares of SILQ would then be converted into shares of Bioethics common stock pursuant to the definitive merger agreement. Following the closing of the transaction, the parties’ current intention and expectation as set out in the Letter of Intent is that the stockholders of SILQ would own approximately 89% of the fully diluted total outstanding stock of Bioethics, and the stockholders of Bioethics immediately prior to the closing of the transaction, including all current stockholders and all shares to be issued prior to the closing as more fully described in the Letter of Intent, would own 11% of the total outstanding stock of Bioethics following the transaction. In connection with the proposed Merger, Bioethics has agreed to consummate a 1-for-2 reverse stock split. Prior to the proposed Merger, Bioethics intends to issue common or preferred stock convertible into common stock in order to raise money to pay down debt and incentivize and otherwise compensate Bioethics’ officers, directors and consultants, who have not received cash compensation for years. It is currently anticipated that following the closing of the proposed Merger, that there will be at least 50,450,000 shares of Bioethics common stock issued an outstanding. This anticipated post-transaction outstanding stock will include the current outstanding shares of Bioethics after a 1-for-2 reverse stock split, meaning that the ownership of Bioethics of the current Bioethics stockholders, exclusive of all shares to be issued between now and the closing of the transaction, as a percentage of all anticipated outstanding stock will be approximately 1% of all outstanding Bioethics stock following the closing of the transaction. The transaction is subject to due diligence review.
공시 • May 17Bioethics, Ltd. announced delayed 10-Q filingOn 05/15/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 02Bioethics, Ltd. announced delayed annual 10-K filingOn 04/01/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2023, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 16Bioethics, Ltd. announced delayed 10-Q filingOn 05/15/2023, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Aug 16Bioethics, Ltd. announced delayed 10-Q filingOn 08/15/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 17Bioethics, Ltd. announced delayed 10-Q filingOn 05/16/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 01Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Aug 17Bioethics, Ltd. announced delayed 10-Q filingOn 08/16/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 18Bioethics, Ltd. announced delayed 10-Q filingOn 05/17/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 02Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Nov 17Bioethics, Ltd. announced delayed 10-Q filingOn 11/16/2020, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Aug 06XCR Diagnostics, Inc. entered into a non-binding term sheet to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction.XCR Diagnostics, Inc. entered into a non-binding term sheet to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction on July 29, 2020. Pursuant to the term sheet, Bioethics will issue 34.2 million shares of Bioethics common stock post one-for-ten reverse stock split. Bioethics and certain of its creditors and affiliates agree to settle down all the liabilities of Bioethics except for $0.2 million. Post completion of the transaction and reverse stock split stockholders of XCR Diagnostics will have the majority share of Bioethics and XCR Diagnostics will become a financially consolidated subsidiary of Bioethics. Mark Scharmann and Elliott Taylor affiliates of Bioethics agrees to lock-up/leak-out agreement governing their shares. Bioethics will raise at least $0.3 million in a private placement within 90 days of closing. At closing, directors of Bioethics and XCR Diagnostics will resign and XCR Diagnostics will have the right to appoint all the directors of Bioethics. The initial directors are expected to be Mark Powelson, Mark Bagnall, Bruce Chafin, Chuck Morrison and Lynda Merrill. Board advisors will be Brian Caplin and Mark Scharmann. The transaction closing is subject to completion of due diligence of XCR Diagnostics by Bioethics, execution of reverse stock split, execution of definitive agreement document, obtaining necessary third party approvals, approval of the board of Bioethics and XCR Diagnostics, approval by the shareholders of Bioethics and XCR Diagnostics and the term sheet requires Bioethics to complete the private placement. The transaction is expected to close by or before August 28, 2020.